Product Description
Mechanisms of Action: ADRA1A Antagonist,5-HT Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Czech | Ecuador | Estonia | France | Germany | Hungary | Ireland | Italy | Latvia | Lebanon | Lithuania | Luxembourg | Netherlands | Pakistan | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | Spain | Switzerland | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypertension|Pre-Eclampsia|Stroke|Cerebrovascular Disorders|Eclampsia
Phase 2: Arthritis, Rheumatoid|Coronary Artery Disease|Spondylitis, Ankylosing|Arthritis, Psoriatic
Phase 1: Hypertension|Arthritis, Rheumatoid|Aneurysm, Dissecting|Aortic Aneurysm
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| YXLL-KY-2024(066) | N/A |
Not yet recruiting |
Cerebral Hemorrhage|Intracranial Hemorrhage, Hypertensive |
2026-11-01 |
|
| INTERACT4 | P3 |
Completed |
Cerebrovascular Disorders|Stroke |
2023-11-23 |
|
| Uranic | P3 |
Terminated |
Pre-Eclampsia|Hypertension |
2020-08-01 |
|
| RAID | P1 |
Unknown status |
Aneurysm, Dissecting|Aortic Aneurysm|Hypertension |
2018-12-01 |